Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605637 | 0.86 | ADRB2 (0.61) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL14750964 | 0.82 | MAPT (0.51) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL19196175 | 0.80 | LMNA (0.63) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL19181215 | 0.80 | LMNA (0.63) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL16360835 | 0.80 | GAA (0.49) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL1040562 | 0.80 | MAPT (0.76) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL6479296 | 0.78 | ADRB3 (0.53) | MAPTALDH1A1POLBADRB2ADRB1 | |
| SCHEMBL2554466 | 0.76 | ALDH1A1 (0.58) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL27940296 | 0.74 | MAPT (0.67) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL12266461 | 0.73 | KMT2A (0.71) | MEN1KMT2AALDH1A1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | PKD1, PCSK9, SLC10A1 | MAPT 443/4885SMN1; SMN2 73/4885MEN1 56/4885 |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | PKD1, PCSK9, SLC10A1 | MAPT 443/4885SMN1; SMN2 73/4885MEN1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.